Name
Midostaurin
Alternate Names
Rydapt
Midostaurine
Abbreviations
None
Category
Chemotherapy
Subcategory
Cytostatic agent--protein kinase inhibitor
NSC Number
None
Primary Site
Leukemia
other cancer
Histology
None
Remarks
4/28/2017: FDA approved midostaurin, trade name Rydapt, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.
Coding
This drug should be coded